Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
[google_news title=”” keyword=”macular degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Age-related macular degeneration (AMD) signs after Dame Judi Dench's admissionon November 26, 2022 at 10:00 pm
Dame Judi Dench's age-related macular degeneration (AMD) has left her and thousands of others struggling to see. The actress sat down to discuss her career and lifetime in showbiz with world-renowned ...
- Age-related Macular Degeneration Market 2022 Statistics, Share Price, Growth Prospects, Industry Trends till 2028on November 26, 2022 at 5:03 am
Final Report will add the analysis of the impact of Russia-Ukraine War and COVID-19 on this industry. "Age-related ...
- Rokid and Eyedaptic Launch EYE5 to Help AMD Patients Enhance Their Visionon November 23, 2022 at 8:20 pm
Rokid, an augmented reality glasses manufacturer, partnered with Eyedaptic to unveil the all-new EYE5 smart glasses at the American Academy of Optometry 2022 Annual Meeting and Expo. The latest model ...
- Wet macular degenerationon November 23, 2022 at 5:15 am
Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into ...
- Dry macular degenerationon November 23, 2022 at 5:15 am
Dry macular degeneration is a common eye disorder among people over 50. It causes blurred or reduced central vision due to the breaking down of the inner layers of the macula (MAK-u-luh).
- Age Related Macular Degeneration Drugs Market 2023 : Production Capacity, Restring Drivers, Size and Landscape Outlook 2028on November 23, 2022 at 3:52 am
Final Report will add the analysis of the impact of Russia-Ukraine War and COVID-19 on this industry. "Age Related ...
- Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharmaon November 22, 2022 at 10:08 am
Regeneron Pharmaceuticals is hoping to establish itself as a major oncology player. See why I no longer see REGN stock price upside in the near term.
- Macular Degeneration Treatment Market Share Size Worth USD 13108.05 Million at a Healthy CAGR, During the Forecast Period 2028on November 22, 2022 at 5:02 am
A wide-reaching Macular Degeneration Treatment Market research report brings into focus the key market dynamics of the sector. This market study also analyzes the market status, market share, growth ...
- Age-related macular degeneration strongly associated with serious forms of cardiovascular diseaseon November 21, 2022 at 4:56 am
Subretinal drusenoid deposits (SDD) are a form of age-related macular degeneration People with SSD are more likely to have cardiovascular disease associated with increased risk of stroke Researchers ...
- Age-Related Macular Degeneration Linked to Severe Vascular Diseaseon November 18, 2022 at 11:30 am
Among patients with age-related macular degeneration (AMD), those whose eyes have signs of subretinal drusenoid deposits (SDDs) are more likely to have high-risk vascular disease (HRVD) than those who ...
via Google News and Bing News